 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In trading on Thursday, shares of OmniAb Inc (OABI) crossed below their 200 day moving average of 4.51, changing hands as low as 4.42 per share. OmniAb Inc shares are currently trading...

OABI Crosses Below Key Moving Average Level

OmniAb (NASDAQ:OABI  Get Free Report)s stock had its buy rating reiterated by equities researchers at Benchmark in a research report issued to clients and investors on...

OmniAb (NASDAQ:OABI) Given Buy Rating at Benchmark

OmniAb, Inc. (NASDAQ:OABI  Get Free Report) CEO Matthew W. Foehr bought 95,000 shares of the stock in a transaction on Friday, November 10th. The stock was purchased at an average price of...

OmniAb, Inc. (NASDAQ:OABI) CEO Purchases $405,650.00 in Stock

Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Airgain (AIRG Research Report), OmniAb (OABI R...

Analysts' Opinions Are Mixed on These Technology Stocks: Airgain (AIRG), OmniAb (OABI) and Par Technology (PAR)

OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed the Companys technology offerings and highlighted...

OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

OmniAb reports Q3 EPS (16c), consensus (14c)

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates. Our business momentum has...

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference, November 14-15, 2023 at the...

OmniAb to Participate in Two Investor Conferences in November

OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time. The two-hour event will include...

OmniAb Announces Agenda for its Research & Technology Virtual Event

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Watchers	177
52-Wk Low	$3.06
52-Wk High	$5.98

Market Cap	$534.7M
Volume (M)	452,335.00
52-Wk High	$5.98
52-Wk Low	$3.06

OABI OmniAb Inc

About

Feed

News

Sentiment

Fundamentals